Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Purchased by Avantax Advisory Services Inc.

Avantax Advisory Services Inc. grew its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 42.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,279 shares of the company’s stock after acquiring an additional 382 shares during the period. Avantax Advisory Services Inc.’s holdings in Medpace were worth $425,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of MEDP. GSA Capital Partners LLP acquired a new stake in Medpace during the 3rd quarter valued at approximately $276,000. Natixis Advisors LLC acquired a new stake in shares of Medpace during the third quarter worth approximately $3,754,000. Thrivent Financial for Lutherans increased its stake in shares of Medpace by 61.3% in the third quarter. Thrivent Financial for Lutherans now owns 14,430 shares of the company’s stock worth $4,817,000 after buying an additional 5,484 shares during the last quarter. Advisors Asset Management Inc. raised its holdings in Medpace by 16.1% in the third quarter. Advisors Asset Management Inc. now owns 6,149 shares of the company’s stock valued at $2,053,000 after acquiring an additional 854 shares in the last quarter. Finally, Raymond James Trust N.A. boosted its stake in Medpace by 34.6% during the 3rd quarter. Raymond James Trust N.A. now owns 754 shares of the company’s stock valued at $252,000 after acquiring an additional 194 shares during the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Stock Up 1.4 %

Shares of NASDAQ:MEDP opened at $324.23 on Monday. The company has a market cap of $9.88 billion, a PE ratio of 25.67, a P/E/G ratio of 3.81 and a beta of 1.47. Medpace Holdings, Inc. has a fifty-two week low of $302.01 and a fifty-two week high of $459.77. The firm has a 50-day simple moving average of $337.72 and a 200 day simple moving average of $339.77.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, research analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Robert W. Baird boosted their target price on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $381.44.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.